Huntington's disease: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• HTT 2
• NRF2 0
• BDNF 1
• STING 0
• AKT 0
• AMPK 0
• NLRP3 0
• SIRT1 0
• PI3K 0
• HMGB1 0
• PPAR 0
• C9orf72 0
• HDAC 0
• HIF-1 0
• HSP90 0
• NMDA 0
• TDP-43 0
• TLR4 0
• APP 0
• BCL-2 0
• CD30 0
• CFTR 1
• CTNNB1 0
• DMD 1
• ERK 0
• EZH2 0
• G6PD 0
• GLP-1 0
• GPX4 0
• IL-17 0
• JNK 0
• MMP-9 0
• mTOR 0
• NF1 1
• PINK1 0
• PSEN1 0
• SMN1 1
• SOD1 0
• STAT3 0
• TP53 0
• YAP 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 573 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

  NCT04400331· Neurocrine Biosciences· Updated 3 Nov 2026

  “Sponsor Decision”Registry text, quoted unchanged. Source

• Withdrawn

  Facilitating Effective Eating With DoddleBags: A Single-Arm Acceptability Study Of DoddleBags to Assess Impact on Self Feeding Behaviours in a Huntington's Disease Population

  NCT07299682· University of Hull· Updated 28 May 2026

  “No recruitment”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

  NCT05655520· Supernus Pharmaceuticals, Inc.· Updated 17 Dec 2025

  “Internal company decision”Registry text, quoted unchanged. Source

• Terminated

  Couple and Spouse Caregiver in Huntington's Disease

  NCT04394767· University Hospital, Lille· Updated 16 May 2025

  “Sponsor's decision, no more inclusions made since the last extension”Registry text, quoted unchanged. Source

• Terminated

  Biological Sample Collection for Research and Biobanking

  NCT04270604· New York Stem Cell Foundation Research Institute· Updated 2 Aug 2024

  “The study was voluntarily terminated by the PI to focus efforts on an alternative biobanking protocol.”Registry text, quoted unchanged. Source

• Withdrawn

  Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease

  NCT04885114· Voyager Therapeutics· Updated 16 Aug 2021

  “We have discontinued our 1st generation HD program with the VYTAL Study \& have initiated a 2nd generation program using a novel, proprietary AAV capsid that may enable intravenous administration \& achieve widespread distribution to affected tissue.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Creatine and Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation Plus Home-Based Exercise for Sarcopenia in Huntington's Disease

  NCT07902206· Universidad de Burgos· Source

• Feasibility and Acceptability of an LLM-based Chatbot for Family Caregivers: Evaluation Study

  NCT07280650· University of Michigan· Source

• A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Novartis Pharmaceuticals· Source

• Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China

  NCT07601516· Teva Branded Pharmaceutical Products R&D LLC· Source

• GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

  NCT05686551· Hoffmann-La Roche· Source

• HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

  NCT02855476· University College, London· Source

• Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease

  NCT07451613· Leslie Thompson· Source

• Autobiographical Memory, Future Thought, and Eye Movements in Huntington's Disease

  NCT07409597· University Hospital, Angers· Source

• Home-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease

  NCT06843252· The University of Texas Health Science Center at San Antonio· Source

• Project AWARE 2.0 to Improve Awareness, Willingness and Ability for Research and Enrollment in Clinical Research

  NCT06343220· Huntington Study Group· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 4
• Organoids 4
• CRISPR-Cas Systems 11
• Gene Expression Profiling 13
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Proteomics 10
• Metabolomics 1
• Mass Spectrometry 1
• Immunohistochemistry 2
• Liquid Biopsy 1
• Positron-Emission Tomography 9
• Magnetic Resonance Imaging 28
• Machine Learning 11
• Deep Learning 4
• Cohort Studies 8
• Genome-Wide Association Study 6

• A deep learning model for speech-based prediction of clinical scores in people with Huntington's disease: a longitudinal study with cross-sectional replication.

  Lancet Digit Health, Jul 2026

• Advancing biomedical data analytics using explainable neural network-based learning model for progressive neurodegenerative disorder diagnosis.

  Sci Rep, Jun 2026

• Development of an Interpretable Deep Learning-Based Segmentation Algorithm for Automated Assessment of Oral Diadochokinesis in Progressive Neurological Diseases.

  J Speech Lang Hear Res, May 2026

• Machine learning and deep learning in clinical practice: Advancing neurodegenerative disease diagnosis with multimodal markers.

  Brain Res Bull, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.